Sipahi Cimen Sevgi, Sayili Sena Baykara
University Of Health Sciences, Sisli Etfal Research and Training Hospital, Department of Pediatrics, Division of Pediatric Allergy and Immunology, Istanbul, Turkey.
Istanbul Training and Research Hospital, Emergency Department, Istanbul, Turkey.
Asia Pac Allergy. 2022 Oct 27;12(4):e41. doi: 10.5415/apallergy.2022.12.e41. eCollection 2022 Oct.
Anaphylaxis is defined as a severe, life-threatening systemic hypersensitivity reaction. Healthcare professionals must recognize the symptoms, apply correct treatment immediately, and provide epinephrine auto-injectors (EAI) to patients who experience anaphylaxis.
In this study, we aimed to investigate the knowledge of healthcare professionals regarding anaphylaxis.
This cross-sectional study, which was conducted between February 2022 and March 2022, included healthcare professionals working in various hospitals in Turkey. A survey consisting of 21 questions which concerned with the demographic data, personal experience and level of knowledge about anaphylaxis was applied to healthcare professionals.
The study included a total of 301 participants, comprising 160 specialist physicians (53.16%), 86 resident physicians (28.57%), 31 family physicians (10.3%), and 24 allied health personnel (7.97%). Most of the healthcare professionals (93%) chose epinephrine as the first-line treatment for anaphylaxis. Two hundred ten participants (69.77%) knew the correct dose of epinephrine in the treatment of anaphylaxis, and allied healthcare professionals had least knowledge ( = 0.009). The participants who received anaphylaxis training and had experience with anaphylaxis had a higher knowledge about epinephrine dosing ( < 0.001 and = 0.003, respectively). Only 49.17% of the participants knew the epinephrine doses of EAIs, and only 19% of participants had prescribed an EAI.
Our results showed that healthcare professionals' knowledge about epinephrine doses in the treatment of anaphylaxis was not sufficient. Furthermore, the prescribing rate of EAIs was still inadequate. There is a need for national training programs to increase and update the knowledge of healthcare professionals to reduce anaphylaxis mortality.
过敏反应被定义为一种严重的、危及生命的全身性超敏反应。医疗保健专业人员必须识别症状,立即进行正确治疗,并为发生过敏反应的患者提供肾上腺素自动注射器(EAI)。
在本研究中,我们旨在调查医疗保健专业人员对过敏反应的了解情况。
这项横断面研究于2022年2月至2022年3月进行,纳入了在土耳其各医院工作的医疗保健专业人员。向医疗保健专业人员发放了一份包含21个问题的调查问卷,这些问题涉及人口统计学数据、个人经历以及对过敏反应的了解程度。
该研究共纳入301名参与者,包括160名专科医生(53.16%)、86名住院医生(28.57%)、31名家庭医生(10.3%)和24名专职医疗人员(7.97%)。大多数医疗保健专业人员(93%)选择肾上腺素作为过敏反应的一线治疗药物。210名参与者(69.77%)知道治疗过敏反应时肾上腺素的正确剂量,专职医疗人员的了解程度最低(P = 0.009)。接受过过敏反应培训且有过敏反应治疗经验的参与者对肾上腺素剂量的了解程度更高(分别为P < 0.001和P = 0.003)。只有49.17%的参与者知道EAI的肾上腺素剂量,只有19%的参与者曾开具过EAI处方。
我们的结果表明,医疗保健专业人员对治疗过敏反应时肾上腺素剂量的了解不足。此外,EAI的处方率仍然不足。需要开展国家培训项目,以增加和更新医疗保健专业人员的知识,降低过敏反应死亡率。